FINHUB Insights

MRK · Q1 FY25 · Jan 1 – Mar 31, 2025

Merck & Q1 FY25: where the revenue came from and where it went

Merck & Q1 FY25: revenue $15.5B (−2% year over year). Net profit $5.1B. Largest cohort US $8.5B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jan 1 – Mar 31, 2025
Reported
May 2, 2025 10-Q
Sankey diagram of Merck &'s income statement for Q1 FY25: revenue of $15.5 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$15.5B −2% year over year
Gross profit$12.1B 78% margin
Operating profit$5.9B 38% margin
Net profit$5.1B 33% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY25 (period ends Mar 31, 2025).
ItemValueShare of revenueYear over year
Revenue 15.5 100% −2%
US 8.5 55% +14%
EMEA 3.5 23% −3%
Latin America 0.8 5% −1%
CN 0.7 5% −60%
Other Countries 0.7 5% +13%
Asia Pacific 0.7 5% −5%
JP 0.7 5% −19%
Cost of revenue−3.422%
Gross profit12.178% margin+0pp
Research & development−3.623%−2pp
SG&A−2.616%+1pp
Operating profit5.938% margin+0pp
Tax−0.8
Net profit5.133%+3pp
Filing on EDGAR More quarters of MRK

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters